Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Terence Hill

Interventional Cardiology Concord, NC Medical Doctor

NPI 1063701019 CMS profile 763947

100 Medical Park Dr, Ste 210, Concord, NC 28025

Open in the dashboard

General payments

$10,407

135 records reported · program years 2019–2025

Research payments

$108

Paid to them · 1 record reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Terence Hill of Concord, NC is reported in the CMS Open Payments database as having received $10,407 across 135 general payments and $108 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 59th percentile of Interventional Cardiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

8 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,971 20
2024 General $3,171 37
2024 Research $108 1
2023 General $631 9
2022 General $1,565 16
2021 General $605 10
2020 General $81 4
2019 General $2,382 39

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Terence Hill
  • Interventional Cardiology median
  • Middle half of Interventional Cardiology
  • National median

In program year 2025, general payments to Terence Hill were reported at $1,971. Among 6,173 Interventional Cardiology profiles paid that year, the median was $1,092 and the middle half received between $366 and $3,019.

Show as a table
Year Terence Hill Interventional Cardiology median Middle half National median
2019 $2,382 $1,097 $329–$3,048 $163
2020 $81 $473 $161–$1,480 $114
2021 $605 $677 $233–$1,827 $132
2022 $1,565 $978 $333–$2,724 $149
2023 $631 $1,136 $382–$2,986 $160
2024 $3,171 $1,181 $395–$3,326 $164
2025 $1,971 $1,092 $366–$3,019 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Edwards Lifesciences Corporation $2,521 36 payments
  2. Abbott Laboratories $2,297 22 payments
  3. Boston Scientific Corporation $1,796 26 payments
  4. Medtronic Vascular, Inc. $1,596 17 payments
  5. Medtronic, Inc. $565 11 payments
  6. Teleflex LLC $427 4 payments
  7. Philips Electronics North America Corporation $277 5 payments
  8. Abiomed $239 2 payments
  9. Inari Medical, Inc. $235 2 payments
  10. Biotronik Inc. $128 1 payment
  11. Other $327 9 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $7,745 125 payments
  2. Travel and Lodging $2,662 10 payments
Products named General payments · program years 2019–2025
  1. CoreValve Evolut $1,328 14 payments
  2. MITRACLIP Vascular $1,217 8 payments
  3. SAPIEN 3 Ultra RESILIA $972 12 payments
  4. EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) $845 7 payments
  5. MITRACLIP Vascular $464 7 payments
  6. AVVIGO Guidance System $387 3 payments
  7. COREVALVE EVOLUT R $361 4 payments
  8. Resolute $267 3 payments
  9. CT THROMBECTOMY SYSTEM KIT $257 3 payments
  10. FLOWTRIEVER CATHETER, S $257 3 payments
  11. Other $3,664 69 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Abiomed $108 1 payment

Prescribing to Medicare patients

Part D · data year 2024 · 23 drugs

Part D claims

790

Median for Interventional Cardiology: 2,236

Drug cost

$97,370

Median for Interventional Cardiology: $380,412

Branded share of claims

44.8%

Median for Interventional Cardiology: 27.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 57 $48,211
Repatha Sureclick Evolocumab Brand 31 $28,435
Brilinta Ticagrelor Brand 16 $7,775
Farxiga Dapagliflozin Propanediol Brand 11 $7,389
Clopidogrel Clopidogrel Bisulfate Brand 153 $1,292
Isosorbide Mononitrate Er Isosorbide Mononitrate Brand 67 $644
Atorvastatin Calcium Generic 78 $608
Nitroglycerin Generic 32 $371
Ezetimibe Generic 14 $297
Amlodipine Besylate Generic 41 $270

The 10 drugs with the highest cost, of 23 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 4,694 Part D prescribers listed as Interventional Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 52 billing codes

Paid by Medicare

$138,161

Medicare's payments for the services billed

Medicare patients

394

Average age 76

Services billed

1,089

173 women, 221 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 75%
Heart failure 61%
Atrial fibrillation 52%
Arthritis 47%
Diabetes 41%
Chronic kidney disease 40%
Depression 29%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

136 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Interventional Cardiology in North Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record